KOĀTE® An Antihemophilic Factor (Human) Lyophilized Powder for Solution for Intravenous Injection

**INDICATIONS AND USAGE**

KOĀTE® is a human plasma-derived antihemophilic factor indicated for the control and prevention of bleeding episodes in patients with hemophilia A (hereditary Factor VIII deficiency). (1)

**INDICATIONS**

- For intravenous use after reconstitution only.
- Each vial of KOĀTE contains the labeled amount of Factor VIII in international units (IU). (2)

**CONTRAINDICATIONS**

- Hypersensitivity reactions, including anaphylaxis, to KOĀTE or its components. (4)

**WARNINGS AND PRECAUTIONS**

- Hypersensitivity reactions, including anaphylaxis, are possible. Severe symptoms occur, discontinue KOĀTE and administer appropriate treatment. (5.1)
- Development of neutralizing antibodies (inhibitors) may occur. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. (5.2)
- Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B or AB blood groups who are receiving large or frequent doses. (5.3)
- KOĀTE is made from human blood and therefore carries a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD), and other blood-borne pathogens. (5.4)

**ADVERSE REACTIONS**

- The most common adverse drug reactions (frequency ≥ 5% of subjects) observed in the clinical trial were nervousness, headache, abdominal pain, diarrhea, nausea, abdominal distension, peritonitis and rash. (11)

**DOSE AND ADMINISTRATION**

- Dose and duration of treatment depend on the severity of the Factor VIII deficiency, location and extent of bleeding, and the patient's clinical condition. (2.1)
- Each vial of KOĀTE is labeled with the actual Factor VIII potency in international units (IU). Calculation of the required dose of Factor VIII is based on the empirical finding that one IU of Factor VIII per kg body weight raises the plasma Factor VIII activity by approximately 2% of normal activity or 2 IU/dL. (2.2)
- The required dose can be determined using the following formula:
  \[
  \text{Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (% normal or IU/dL) x 0.5}
  \]
- Estimate the expected peak increase in Factor VIII level, expressed as IU/dL or % normal, using the following formula:
  \[
  \text{Estimated Increment of Factor VIII (% normal or IU/dL) = Total Dose (IU)/Body Weight (kg)) x 2}
  \]
- Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses. Base the dose and frequency on the individual clinical response. (2.3)

**DOSAGE AND ADMINISTRATION**

- For intravenous use after reconstitution only.
- Dose

  - Large bruises
  - Significant cuts or scrapes
  - Uncomplicated joint hemorrhage

  - Estimate the expected peak increase in Factor VIII level, expressed as IU/dL or % normal, using the following formula:
  \[
  \text{Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (% normal or IU/dL) x 0.5}
  \]

**ADVERSE REACTIONS**

- The most common adverse drug reactions (frequency ≥ 5% of subjects) observed in the clinical trial were nervousness, headache, abdominal pain, diarrhea, nausea, abdominal distension, peritonitis and rash. (11)

**DOSE AND ADMINISTRATION**

- Dose and duration of treatment depend on the severity of the Factor VIII deficiency, location and extent of bleeding, and the patient's clinical condition. (2.1)
- Each vial of KOĀTE is labeled with the actual Factor VIII potency in international units (IU). Calculation of the required dose of Factor VIII is based on the empirical finding that one IU of Factor VIII per kg body weight raises the plasma Factor VIII activity by approximately 2% of normal activity or 2 IU/dL. (2.2)
- The required dose can be determined using the following formula:
  \[
  \text{Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (% normal or IU/dL) x 0.5}
  \]
- Estimate the expected peak increase in Factor VIII level, expressed as IU/dL or % normal, using the following formula:
  \[
  \text{Estimated Increment of Factor VIII (% normal or IU/dL) = Total Dose (IU)/Body Weight (kg)) x 2}
  \]
- Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses. Base the dose and frequency on the individual clinical response. (2.3)

**DOSAGE AND ADMINISTRATION**

- For intravenous use after reconstitution only.
- Dose

  - Large bruises
  - Significant cuts or scrapes
  - Uncomplicated joint hemorrhage

  - Estimate the expected peak increase in Factor VIII level, expressed as IU/dL or % normal, using the following formula:
  \[
  \text{Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (% normal or IU/dL) x 0.5}
  \]
- Estimate the expected peak increase in Factor VIII level, expressed as IU/dL or % normal, using the following formula:
  \[
  \text{Estimated Increment of Factor VIII (% normal or IU/dL) = Total Dose (IU)/Body Weight (kg)) x 2}
  \]
- Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses. Base the dose and frequency on the individual clinical response. (2.3)

**DOSAGE AND ADMINISTRATION**

- For intravenous use after reconstitution only.
- Dose

  - Large bruises
  - Significant cuts or scrapes
  - Uncomplicated joint hemorrhage

  - Estimate the expected peak increase in Factor VIII level, expressed as IU/dL or % normal, using the following formula:
  \[
  \text{Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (% normal or IU/dL) x 0.5}
  \]
- Estimate the expected peak increase in Factor VIII level, expressed as IU/dL or % normal, using the following formula:
  \[
  \text{Estimated Increment of Factor VIII (% normal or IU/dL) = Total Dose (IU)/Body Weight (kg)) x 2}
  \]
- Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses. Base the dose and frequency on the individual clinical response. (2.3)
3 DOSAGE FORMS AND STRENGTHS
KOĀTE® (Antithrombin Factor [Human]) is available as a lyophilized powder for reconstitution in single-use vials of 250, 500 and 1,000 IU of Factor VIII activity. The actual Factor VIII potency is labeled on each KOĀTE vial.

4 CONTRAINdicATIONS
KOĀTE is contraindicated in patients who have had hypersensitivity reactions, including anaphylaxis, to KOĀTE or its components. [See Description (5.5)].

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, are possible. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paralysis, restlessness, wheezing and dyspnea. If these signs develop, discontinue use of the product immediately and administer appropriate emergency treatment.

5.2 Neutralizing Antibodies
The formation of neutralizing antibodies (inhibitors) to Factor VIII may occur. Monitor all patients for the development of Factor VIII inhibitors by separate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. [See Warnings and Precautions (5.5)].

5.3 Intravascular Hemolysis
KOĀTE contains blood group isoglutamides which are not clinically significant when small doses are used to treat minor bleeding episodes. However, when large and/or frequent doses of KOĀTE are given to patients with blood groups A, B, or AB, acute hemolytic anemia may occur, resulting in increased bleeding tendency or hyperfibrinogenemia. Monitor these patients for signs of intravascular hemolysis and falling hematocrit. [See Warnings and Precautions (5.5)]. Should this condition occur, leading to progressive hemolytic anemia, discontinue KOĀTE and consider administering semisynthetic compatible Type O red blood cells and providing alternative therapy.

5.4 Transmissible Infectious Agents
Because KOĀTE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product. The risk that the product will transmit viruses has been reduced by screening plasma donors for prior history of certain current and infectious diseases, by inactivating and removing certain viruses during manufacture. Despite these measures, this product may still potentially transmit diseases.

5.5 Monitoring: Laboratory Tests
Whole plasma. When reconstituted as directed, KOĀTE contains approximately 50 to 150 times as much Factor VIII as an equal volume of polysorbate 80) treatment and heat treatment of the lyophilized final container. A gel permeation chromatography step serves the dual purpose of removing contaminating DNA viruses and the factor VIII inhibitor. The pharmacokinetics (PK) of KOĀTE were evaluated in a prospective, two-stage clinical trial of 20 previously treated patients (PTPs) with severe hemophilia A. In Stage I, the PK parameters for 19 subjects were based on plasma Factor VIII activity after a single intravenous infusion of 50 IU/kg of KOĀTE. Bacteriuria of the dry heat-treated KOĀTE in the unethical KOĀTE was demonstrated by comparison of Cmax and the area under the curve, AUC0-24 (Table 3). The incremental in-rho recovery ten minutes after infusion of dry heat-treated KOĀTE was 1.50-fold (unheated KOĀTE was 1.82% uptake). Mean biologic half-life was 16.1 hours. In Stage II of the study, patients received KOĀTE treatments for six months on home therapy with a median of 52 days (range 23 to 54 days). At the end of 6 months, the mean AUC0-24 was 147 ± 237 unit.hour/100 mL, the Cmax was 99 ± 13 unit/100 mL, and the t1/2 was 16 ± 3.9 hours.

5.6 ADVERSE REACTIONS
The most common adverse drug reactions (frequency ≥ 5% of subjects) observed in the clinical trial were nervousness, headache, abdominal pain, nausea and blurred vision.

6.1 Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.

6.2 Postmarketing Experience
Because postmarketing reporting of adverse reactions is voluntary and from a population of unknown size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.

6.3 Storage and Handling
KOĀTE contains Antithrombin (human) in single-use vials for reconstitution and a wiper device. Shop KOĀTE at controlled room temperature and avoid freezing. Store KOĀTE in the original carton at room temperature and out of direct sunlight. KOĀTE is flammable. The actual Factor VIII potency is labeled on each carton and vial label.

7.1 Pregnancy
Risk Summary
There are no data with KOĀTE use in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted. KOĀTE is contraindicated in pregnant patients because the risk of the product to the fetus cannot be ruled out. Women of child-bearing potential should be advised to use effective contraceptive measures during treatment with the product.

7.2 Lactation
Risk Summary
There is no information regarding the presence of KOĀTE in human milk, the effects on the breastfed infant, or the effects on milk production.

7.3 Pediatric Use
Safety and efficacy studies have been performed in 22 previously treated pediatric patients aged 2.5 to 16 years. Subjects received 200 IU/kg of KOĀTE for treatment or control of bleeding episodes, including perioperative management, and routine prophylaxis. Children have shorter half-life and lower recovery of Factor VIII than adults. Because clearance of Factor VIII (based on per kilogram body weight) is higher in children, lower or more frequent dosing may be needed.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Risk Summary
There are no data with KOĀTE use in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted. KOĀTE is contraindicated in pregnant patients because the risk of the product to the fetus cannot be ruled out. Women of child-bearing potential should be advised to use effective contraceptive measures during treatment with the product.

8.2 Lactation
Risk Summary
There is no information regarding the presence of KOĀTE in human milk, the effects on the breastfed infant, or the effects on milk production.

8.3 Pediatric Use
Safety and efficacy studies have been performed in 22 previously treated pediatric patients aged 2.5 to 16 years. Subjects received 200 IU/kg of KOĀTE for treatment or control of bleeding episodes, including perioperative management, and routine prophylaxis. Children have shorter half-life and lower recovery of Factor VIII than adults. Because clearance of Factor VIII (based on per kilogram body weight) is higher in children, higher or more frequent dosing may be needed.

8.4 Geriatric Use
Clinical studies of KOĀTE did not include any subjects aged 65 and over to determine whether they respond differently from younger subjects. Individual dose selection for geriatric patients.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
KOĀTE temporarily replaces the missing clotting Factor VIII that is needed for effective hemostasis.

12.2 Pharmacodynamics
Hemophilia A is a bleeding disorder characterized by a deficiency of functional coagulation Factor VIII, resulting in a prolonged plasma clotting time as measured by the activated partial thromboplastin time (aPTT). Treatment with KOĀTE normalizes the aPTT over the effective dosing period.

12.3 Pharmacokinetics
The pharmacokinetics (PK) of KOĀTE were evaluated in a prospective, two-stage clinical trial of 20 previously treated patients (PTPs) with severe hemophilia A. In Stage I, the PK parameters for 19 subjects were based on plasma Factor VIII activity after a single intravenous infusion of 50 IU/kg of KOĀTE. Bacteriuria of the dry heat-treated KOĀTE in the unethical KOĀTE was demonstrated by comparison of Cmax and the area under the curve, AUC0-24 (Table 3). The incremental in-rho recovery ten minutes after infusion of dry heat-treated KOĀTE was 1.50-fold (unheated KOĀTE was 1.82% uptake). Mean biologic half-life was 16.1 hours. In Stage II of the study, patients received KOĀTE treatments for six months on home therapy with a median of 52 days (range 23 to 54 days). At the end of 6 months, the mean AUC0-24 was 147 ± 237 unit.hour/100 mL, the Cmax was 99 ± 13 unit/100 mL, and the t1/2 was 16 ± 3.9 hours.

13 REFERENCES

14 HOW SUPPLIED/STORAGE AND HANDLING
KOĀTE is supplied in single-use vials containing 250, 500 or 1,000 IU of Factor VIII activity, packaged with 5 mL or 10 mL of Sterile Water for Injection in a Mix2Vial transfer device. The actual and recommended strength is stated on each carton and vial label. Components used in the packaging of KOĀTE are not made with natural rubber latex.